You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

 

Online download statistics by month:

Online download statistics by month: January 2021 to July 2025

AbstractFullPdf
Jan 2021423423125
Feb 202127127396
Mar 202116216182
Apr 2021898977
May 2021133133100
Jun 202111111168
Jul 202110110159
Aug 202111211254
Sep 2021999947
Oct 2021919161
Nov 2021979786
Dec 202111011058
Jan 202221922945
Feb 2022445238
Mar 2022657044
Apr 20228711564
May 202210712267
Jun 202213313671
Jul 2022828629
Aug 2022838961
Sep 2022758356
Oct 2022718163
Nov 20226911459
Dec 2022636536
Jan 2023727429
Feb 2023858529
Mar 2023777932
Apr 2023505130
May 2023797936
Jun 2023383824
Jul 2023414127
Aug 2023242418
Sep 2023424215
Oct 2023323219
Nov 2023606131
Dec 2023707037
Jan 2024373815
Feb 2024444438
Mar 2024535363
Apr 2024454733
May 2024272731
Jun 2024485130
Jul 2024414528
Aug 2024353899
Sep 2024363626
Oct 2024495035
Nov 2024586027
Dec 2024333422
Jan 2025525219
Feb 2025959544
Mar 2025656537
Apr 2025767642
May 2025353642
Jun 2025353619
Jul 2025110
Total443246022523